PMID- 28418115
OWN - NLM
STAT- MEDLINE
DCOM- 20180821
LR  - 20240313
IS  - 2040-1124 (Electronic)
IS  - 2040-1116 (Print)
IS  - 2040-1116 (Linking)
VI  - 9
IP  - 2
DP  - 2018 Mar
TI  - Aggravation of diabetes, and incompletely deficient insulin secretion in a case 
      with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with 
      nivolumab.
PG  - 438-441
LID - 10.1111/jdi.12679 [doi]
AB  - Anti-programmed cell death-1 (PD-1) antibody therapy induces various adverse 
      effects, especially in the endocrine system. Several cases of acute-onset 
      insulin-dependent diabetes after anti-PD-1 antibody therapy have been reported. 
      Many of these cases have a susceptible human leukocyte antigen (HLA) genotype for 
      type 1 diabetes, possibly suggesting that HLA might be involved in the onset of 
      diabetes with anti-PD-1 therapy. We describe an atypical case of hyperglycemia 
      after anti-PD-1 antibody administration. A 68-year-old Japanese man with 
      pancreatic diabetes and steroid diabetes was given nivolumab three times for 
      chemoresistant adenocarcinoma of the lung. On day 5 after the third infusion of 
      nivolumab, he had hyperglycemia (blood glucose 330 mg/dL and hemoglobin A1c 8.0%) 
      without ketosis and with incompletely deficient insulin secretion. The patient 
      had both type 1 diabetes susceptible (HLA-A*24:02 and -DRB1*09:01) and resistant 
      (HLA-DRB1*15:02) HLA genotypes. These HLA genotypes differ from those previously 
      reported in anti-PD-1 antibody-induced diabetes, and might have influenced the 
      preservation of insulin secretion after nivolumab administration in the present 
      case.
CI  - (c) 2017 The Authors. Journal of Diabetes Investigation published by Asian 
      Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, 
      Ltd.
FAU - Matsumura, Kimio
AU  - Matsumura K
AUID- ORCID: 0000-0001-7031-5014
AD  - Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
FAU - Nagasawa, Kaoru
AU  - Nagasawa K
AD  - Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
FAU - Oshima, Yoichi
AU  - Oshima Y
AD  - Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
FAU - Kikuno, Shouta
AU  - Kikuno S
AD  - Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
FAU - Hayashi, Kyohei
AU  - Hayashi K
AD  - Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
FAU - Nishimura, Akihiro
AU  - Nishimura A
AD  - Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
FAU - Okubo, Minoru
AU  - Okubo M
AD  - Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
AD  - Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
FAU - Uruga, Hironori
AU  - Uruga H
AD  - Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
AD  - Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, 
      Tokyo, Japan.
FAU - Kishi, Kazuma
AU  - Kishi K
AD  - Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
AD  - Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, 
      Tokyo, Japan.
FAU - Kobayashi, Tetsuro
AU  - Kobayashi T
AD  - Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
FAU - Mori, Yasumichi
AU  - Mori Y
AD  - Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan.
AD  - Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
LA  - eng
PT  - Case Reports
DEP - 20170613
PL  - Japan
TA  - J Diabetes Investig
JT  - Journal of diabetes investigation
JID - 101520702
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (HLA Antigens)
RN  - 0 (Insulin)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal/*adverse effects
MH  - Antineoplastic Agents/*adverse effects
MH  - Blood Glucose/analysis
MH  - C-Peptide/analysis
MH  - Diabetes Mellitus, Type 1/complications/*genetics/*immunology
MH  - HLA Antigens/*genetics
MH  - Humans
MH  - Hyperglycemia/complications/*immunology
MH  - Insulin/*deficiency/metabolism
MH  - Insulin Secretion
MH  - Lung Neoplasms/complications
MH  - Male
MH  - Nivolumab
PMC - PMC5835466
OTO - NOTNLM
OT  - Anti-programmed death 1 antibody
OT  - Nivolumab
OT  - Type 1 Diabetes
EDAT- 2017/04/19 06:00
MHDA- 2018/08/22 06:00
PMCR- 2018/03/01
CRDT- 2017/04/19 06:00
PHST- 2017/02/23 00:00 [received]
PHST- 2017/03/30 00:00 [revised]
PHST- 2017/04/11 00:00 [accepted]
PHST- 2017/04/19 06:00 [pubmed]
PHST- 2018/08/22 06:00 [medline]
PHST- 2017/04/19 06:00 [entrez]
PHST- 2018/03/01 00:00 [pmc-release]
AID - JDI12679 [pii]
AID - 10.1111/jdi.12679 [doi]
PST - ppublish
SO  - J Diabetes Investig. 2018 Mar;9(2):438-441. doi: 10.1111/jdi.12679. Epub 2017 Jun 
      13.